CD80 is a cell-surface protein that helps regulate T-cell responses. Also called B7-1, it is expressed principally by antigen-presenting cells and acts as a ligand for the receptors CD28 and CTLA-4. Binding to CD28 supports T-cell activation, whereas engagement of CTLA-4 contributes to immune regulation. CD80 therefore participates in both the initiation of adaptive immune responses and the mechanisms that restrain them.
Molecular structure and expression
In humans, CD80 is encoded by the CD80 gene on chromosome 3. It belongs to the B7 family of immune regulatory proteins and is a type I transmembrane glycoprotein: its amino-terminal region lies outside the cell, a single segment crosses the cell membrane, and a short carboxy-terminal tail lies inside the cell.
The extracellular portion contains two immunoglobulin-like domains, one variable-like and one constant-like. These domains provide the structural framework for receptor binding. Glycosylation contributes to the properties of the mature surface protein. CD80 can form homodimers, and its organization at the cell surface influences interactions with its receptors.
CD80 is found particularly on dendritic cells, activated B cells, and macrophages. Expression varies with cell type, activation state, and local signals. It is often increased during antigen-presenting-cell activation, including responses to microbial products and inflammatory signals. Some activated T cells and nonimmune cells can also express CD80 under particular conditions; it is not an exclusive marker of professional antigen-presenting cells.
Role in T-cell costimulation
Activation of a naive T cell usually requires more than recognition of an antigen. The T-cell receptor recognizes a peptide presented by a major histocompatibility complex molecule, providing an antigen-specific signal. CD80 binding to CD28 provides an important additional signal, termed costimulation.
CD28 signaling cooperates with T-cell-receptor signaling to promote cell survival, metabolic activity, proliferation, and production of interleukin-2. This coordination helps couple T-cell activation to the state of the antigen-presenting cell rather than to antigen recognition alone.
When antigen recognition occurs without adequate costimulation, the outcome can include impaired responsiveness, anergy, or deletion rather than productive activation. These outcomes depend on the T-cell population and signaling environment; absence of CD80 alone does not invariably cause tolerance, because other costimulatory pathways can contribute.
CTLA-4 and immune regulation
CD80 also binds CTLA-4, an inhibitory receptor induced on conventional T cells after activation and constitutively expressed by regulatory T cells. CTLA-4 binds CD80 more strongly than CD28 does and can limit access to the ligand. The biological outcome depends on receptor abundance, binding avidity, spatial organization, and the activation state of the interacting cells.
CTLA-4 can also remove CD80 from an antigen-presenting cell through trans-endocytosis: receptor-bound ligand is taken into the CTLA-4-expressing cell and subsequently degraded. This reduces the antigen-presenting cell’s capacity to provide CD28-mediated costimulation.
These interactions contribute to peripheral immune tolerance. CD80 is therefore not simply an activating molecule. The same surface ligand can support an immune response through CD28 or help constrain that response through CTLA-4.
Relationship to CD86 and PD-L1
CD86, also called B7-2, shares CD28 and CTLA-4 as receptors but is a distinct protein. CD86 is often available earlier during antigen-presenting-cell activation, whereas CD80 is frequently induced later. This pattern varies among cell types and experimental conditions.
CD80 and CD86 differ in receptor-binding properties, surface organization, and regulation. Their functions overlap, but neither their expression patterns nor their contributions to an immune response are identical.
CD80 also interacts with PD-L1, a ligand in another immune checkpoint pathway. Interactions between CD80 and PD-L1 on the same cell surface, described as cis interactions, can alter the availability of these molecules for other receptors. Consequently, CD80 function cannot always be inferred from its abundance alone: the other receptors and ligands present on each cell also matter.
Research and therapeutic relevance
CD80 is commonly measured using flow cytometry or tissue-based antibody staining to characterize antigen-presenting cells and examine immune activation. Expression is frequently assessed together with CD86, antigen-presentation molecules, and other markers. CD80 positivity by itself does not establish a cell’s complete functional state or its ability to activate T cells.
The CD80–CD86–CD28–CTLA-4 network is a target of established immune-modulating treatments. CTLA-4–immunoglobulin fusion proteins, including abatacept and belatacept, bind CD80 and CD86 and inhibit their engagement with CD28. Antibodies that block CTLA-4 act differently: they interfere with inhibitory regulation rather than directly blocking CD80-mediated costimulation.
CD80 is also studied in tumor immunology because its expression can affect communication between malignant cells, antigen-presenting cells, and T cells. Its effect is context-dependent, reflecting the balance of activating and inhibitory interactions. Surface expression alone is therefore insufficient to predict an antitumor response or a clinical outcome.